Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults

Summary

This is a phase 1 study to assess the safety and immunogenicity of different formulations of the investigational adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine (SCB-2020S vaccine), when administered as 2 dose vaccination series 21 days apart to adults ≥18 to ≤75 years of age.

Timeline

Start

2022-05-30

Primary completion

2022-09-23

Completion

2023-04-23

Drugs

Indications